Comparing new drug combos for untreated DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study compares three different drug combinations for people with untreated DLBCL. One group gets a standard combination (pola-RCHP), another gets that plus a targeted pill (like orelabrutinib or venetoclax), and a third gets the standard chemo without the targeted antibody. The goal is to see which approach works best and is safest.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have not had any previous treatment for your lymphoma.
- Your lymphoma type is called CD20-positive DLBCL (a common form of Non-Hodgkin Lymphoma).
- Your IPI (International Prognostic Index) score is between 2 and 5, meaning it's at least intermediate risk.
- You are able to be up and about, even if you need to rest some of the day (ECOG score of 0, 1, or 2).
- Your heart is pumping well enough (an LVEF of 50% or more on a heart scan or echo).
- Your blood counts (especially red blood cells, white blood cells, and platelets) are at certain minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This trial tests whether adding a targeted drug (X) to the standard Pola-R-CHP regimen works better for people with DLBCL whose cancer didn't respond well after the first cycle of chemo. It compares the standard treatment to a combination with an extra drug, aiming to improve outcomes for those who need it most.
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
This trial tests a combination of two targeted therapies, polatuzumab vedotin and glofitamab, for people with DLBCL that either came back within 12 months of R-CHOP or never went away. The goal is to see if this two-drug approach can help when standard chemotherapy has not worked well.
This trial tests whether adding zilovertamab vedotin to standard chemo (R-CHP) works better than standard chemo (R-CHOP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to find a more effective treatment option.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.